@CloudExpo Authors: Zakia Bouachraoui, Elizabeth White, Liz McMillan, Pat Romanski, Roger Strukhoff


BioMarin Uses Itamar Medical's Endo-PAT2000 In Successful Phase 2 Study For New Treatment For Sickle Cell Disease

Clinical Study shows that drug improves endothelial function in Sickle Cell Disease patients

Caesarea, Israel Itamar Medical, an international medical technology company developing noninvasive diagnostic technology using the Peripheral Arterial Tone (PAT™) Signal, announced the use of the company's patented Endo-PAT2000 in BioMarin Pharmaceutical Inc.'s phase 2 study of patients with Sickle Cell Disease (SCD). The Endo-PAT2000 was used to measure endothelial function in a study designed to evaluate whether the drug 6R-BH4 can improve endothelial function in SCD patients.

Using measurements obtained from Endo-PAT tests, BioMarin announced Oct. 15 that the oral administration of 6R-BH4 is associated with an improvement of endothelial function in SCD patients. According to the study's key findings, Endo-PAT measurements showed that patients treated with escalating doses of 6R-BH4 showed improved endothelial function at weeks 8, 12 and 16, and that the improvement appeared to be dose dependent. Endo-PAT measurements indicate that patients with endothelial dysfunction at baseline, 56% of the study's patient population, improved to the normal range, with a demonstrated improvement at all dose levels.

Sickle Cell Disease is a chronic, debilitating, lifelong disease that affects a population of approximately 100,000 people in the U.S. In light of new medical research that has shifted focus away from the physical sickling of red blood cells towards the deteriorating health of blood vessels in SCD patients, BioMarin's trial evaluated changes in the physiological and biochemical markers of endothelial function, which underlie key aspects of Sickle Cell Disease.

In BioMarin's announcement, Emil Kakkis, M.D., Ph.D., Chief Medical Officer of BioMarin stated: "The Endo-PAT device is a new reproducible method to measure the effect of endothelial dysfunction on small vessel function and has been adopted by the ongoing Framingham study of cardiovascular risks and outcomes. With this current SCD study, we have an indication that 6R-BH4 is active in improving endothelial function, and we hope to establish a clear relationship between the degree of endothelial dysfunction and the frequency and severity of sickle cell crises using a survey of SCD patients with the Endo-PAT test."

Dov Rubin, President and CEO of Itamar Medical stated: "We see many pharmaceutical companies, big and small, investing significant resources in finding cures for endothelial dysfunction. The fact that BioMarin, like other pharmaceutical companies, chose Itamar Medical's Endo-PAT2000 is not coincidental. The Endo-PAT2000 is the only medical device that is FDA-cleared as an aid in the detection of endothelial dysfunction. We regard the use of Endo-PAT2000 by pharmaceutical companies such as BioMarin and others as an endorsement of the Endo-PAT’s effectiveness and reliability for assessing endothelial function."

Itamar Medical has developed the first simple, inexpensive, office-based non-invasive diagnostic test for endothelial function. Endothelial dysfunction is the earliest stage of cardiovascular disease. The Endo-PAT2000 is a non-invasive device that measures endothelial function by using bio-sensors mounted on the patient's fingers. These sensors measure the PAT signal that reflects minute changes in vascular tone. Endo-PAT2000 adds an important dimension to the prevention of cardiovascular disease by enabling physicians to reliably detect endothelial function and modify patient management accordingly.

Itamar Medical (TASE: ITMR) is a medical technology company developing noninvasive diagnostic systems using Peripheral Arterial Tone (PAT™) signal, including the Watch-PAT™ systems for the diagnosis of sleep related breathing disorders and the Endo-PAT™ systems for assessment of endothelial function, a condition recognized as an early stage of cardiovascular and cerebrovascular diseases.  For further information see http://www.itamar-medical.com.


More Stories By Marissa Levy

Marissa is a technology writer based in Jerusalem, Israel covering the local software, wireless, and start-up markets. Prior to her coverage of Israeli hi-tech, Marissa worked as a reporter in several English language news outlets. Her writing has been featured in prominent publications such as USA TODAY, FOXNews.com, and the Jerusalem Post. She holds degrees in Journalism and Political Science from The George Washington University in Washington, DC. She can be reached at [email protected]

CloudEXPO Stories
The precious oil is extracted from the seeds of prickly pear cactus plant. After taking out the seeds from the fruits, they are adequately dried and then cold pressed to obtain the oil. Indeed, the prickly seed oil is quite expensive. Well, that is understandable when you consider the fact that the seeds are really tiny and each seed contain only about 5% of oil in it at most, plus the seeds are usually handpicked from the fruits. This means it will take tons of these seeds to produce just one bottle of the oil for commercial purpose. But from its medical properties to its culinary importance, skin lightening, moisturizing, and protection abilities, down to its extraordinary hair care properties, prickly seed oil has got lots of excellent rewards for anyone who pays the price.
The platform combines the strengths of Singtel's extensive, intelligent network capabilities with Microsoft's cloud expertise to create a unique solution that sets new standards for IoT applications," said Mr Diomedes Kastanis, Head of IoT at Singtel. "Our solution provides speed, transparency and flexibility, paving the way for a more pervasive use of IoT to accelerate enterprises' digitalisation efforts. AI-powered intelligent connectivity over Microsoft Azure will be the fastest connected path for IoT innovators to scale globally, and the smartest path to cross-device synergy in an instrumented, connected world.
There are many examples of disruption in consumer space – Uber disrupting the cab industry, Airbnb disrupting the hospitality industry and so on; but have you wondered who is disrupting support and operations? AISERA helps make businesses and customers successful by offering consumer-like user experience for support and operations. We have built the world’s first AI-driven IT / HR / Cloud / Customer Support and Operations solution.
ScaleMP is presenting at CloudEXPO 2019, held June 24-26 in Santa Clara, and we’d love to see you there. At the conference, we’ll demonstrate how ScaleMP is solving one of the most vexing challenges for cloud — memory cost and limit of scale — and how our innovative vSMP MemoryONE solution provides affordable larger server memory for the private and public cloud. Please visit us at Booth No. 519 to connect with our experts and learn more about vSMP MemoryONE and how it is already serving some of the world’s largest data centers. Click here to schedule a meeting with our experts and executives.
Darktrace is the world's leading AI company for cyber security. Created by mathematicians from the University of Cambridge, Darktrace's Enterprise Immune System is the first non-consumer application of machine learning to work at scale, across all network types, from physical, virtualized, and cloud, through to IoT and industrial control systems. Installed as a self-configuring cyber defense platform, Darktrace continuously learns what is ‘normal' for all devices and users, updating its understanding as the environment changes.